Maze Therapeutics, Inc. - Bathi saben saham sajroning taun lumaku MAZE

Maze Therapeutics Inc (MAZE) develops genetic drugs, outsourcing primary testing to external CRO centers while maintaining full control over patents. Historical EPS YoY TTM dynamics confirm the effectiveness of the Compass DNA modeling platform, with the latest value recorded as -19.70. The business's financial stability is independent of GDP cycles, relying exclusively on the success of clinical trials and liquidity reserves.
MAZE (Maze Tx): rincian analitis lan laporan miturut indikator

This indicator measures the dynamics of net income per share over the last twelve months relative to the same period last year, reflecting the actual efficiency of value generation. By analyzing the year-over-year EPS (TTM) history on the GURU.Markets platform, a Maze Therapeutics Inc (MAZE) investor can assess the financial pressure that emerged following the collapse of the strategic merger and the company's transition to independent clinical development.